Patents Represented by Attorney James Epperson

Find this attorney in the Justia Lawyer Directory

  • Compounds for the treatment of hepatitis C
    Patent number: 7541352
    Abstract: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.
    Type: Grant
    Filed: January 30, 2008
    Date of Patent: June 2, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kap-Sun Yeung, John F. Kadow, Katharine A. Grant-Young
  • Compounds for the treatment of hepatitis C
    Patent number: 7541351
    Abstract: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.
    Type: Grant
    Filed: January 9, 2008
    Date of Patent: June 2, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: John A. Bender, Min Ding, Robert G. Gentles
  • Compounds for the treatment of hepatitis C
    Patent number: 7541353
    Abstract: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.
    Type: Grant
    Filed: March 11, 2008
    Date of Patent: June 2, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert G. Gentles, Xiaofan Zheng, Min Ding, Yong Tu, Ying Han, Piyasena Hewawasam, John F. Kadow, John A. Bender, Kap-Sun Yeung, Katharine A. Grant-Young, Thomas W. Hudyma
  • Compounds for the treatment of hepatitis C
    Patent number: 7538103
    Abstract: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.
    Type: Grant
    Filed: March 11, 2008
    Date of Patent: May 26, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: Piyasena Hewawasam, Yong Tu
  • Compounds for the treatment of Hepatitis C
    Patent number: 7538102
    Abstract: The invention encompasses compounds of Formula I, pharmaceutically acceptable salts thereof, compositions, and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.
    Type: Grant
    Filed: March 11, 2008
    Date of Patent: May 26, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kap-Sun Yeung, John A. Bender, Robert G. Gentles, Zhong Yang, Min Ding, Yong Tu, Piyasena Hewawasam, Ying Han, John F. Kadow
  • Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
    Patent number: 7521442
    Abstract: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.
    Type: Grant
    Filed: May 23, 2007
    Date of Patent: April 21, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert G. Gentles, Min Ding, Piyasena Hewawasam
  • Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
    Patent number: 7521441
    Abstract: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.
    Type: Grant
    Filed: May 7, 2007
    Date of Patent: April 21, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert G. Gentles, Piyasena Hewawasam, Min Ding, Carl P. Bergstrom, Scott W. Martin, Kap-Sun Yeung, Thomas W. Hudyma, Xiaofan Zheng, John A. Bender, John F. Kadow
  • Compounds for the treatment of hepatitis C
    Patent number: 7521444
    Abstract: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.
    Type: Grant
    Filed: March 11, 2008
    Date of Patent: April 21, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: John A. Bender, Robert G. Gentles, Ying Han, Yong Tu, Zhong Yang, Kap-Sun Yeung, Katharine A. Grant-Young
  • Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
    Patent number: 7521443
    Abstract: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.
    Type: Grant
    Filed: November 19, 2007
    Date of Patent: April 21, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: John A. Bender, Min Ding, Robert G. Gentles, Piyasena Hewawasam
  • Compounds for the treatment of hepatitis C
    Patent number: 7517872
    Abstract: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.
    Type: Grant
    Filed: February 15, 2008
    Date of Patent: April 14, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: Andrew Nickel, John F. Kadow
  • N-[[4-fluoro-2-(5-methy-1H-1,2,4-triazol-1-yl)phenyl]methyl]-4-,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide as an HIV integrase inhibitor
    Patent number: 7511037
    Abstract: The invention encompasses a series of bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.
    Type: Grant
    Filed: August 16, 2006
    Date of Patent: March 31, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: B. Narasimhulu Naidu, Jacques Banville, Francis Beaulieu, Timothy P. Connolly, Mark R. Krystal, John D. Matiskella, Carl Ouellet, Serge Plamondon, Roger Remillard, Margaret E. Sorenson, Yasutsugu Ueda, Michael A. Walker
  • Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation
    Patent number: 7511139
    Abstract: Processes for preparing entecavir and novel intermediates thereof using carbon-silicon oxidation.
    Type: Grant
    Filed: June 2, 2005
    Date of Patent: March 31, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: Maotang X. Zhou, Emily A. Reiff, Purushotham Vemishetti, Yadagiri R. Pendri, Ambarish K. Singh, Siva Josyula Prasad, Ulhas P. Dhokte, Xinhua Qian, Pia Mountford, Kerry B. Hartung, Helen Sailes
  • Substituted imidazo[1,2-a]pyrimidines as HIV viral DNA integrase inhibitors
    Patent number: 7494984
    Abstract: The invention encompasses a series of bicyclic heterocyclic compounds of Formula I which are inhibitors of HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.
    Type: Grant
    Filed: August 29, 2006
    Date of Patent: February 24, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jacques Banville, Roger Remillard, Serge Plamondon
  • Cycloalkylamine derivatives as NK-1/SSRI antagonists
    Patent number: 7494986
    Abstract: The present disclosure relates to chemical compounds and their use in human therapy. A specific embodiment relates to compounds of Formula (I) or an isomer, a pharmaceutically acceptable salt or solvate thereof and pharmaceutically acceptable formulations comprising said compounds useful for the treatment or prevention of conditions mediated by tachykinins and/or selective inhibition of serotonin reuptake transporter protein. The compounds act as dual NK-1 antagonists and selective serotonin reuptake inhibitors.
    Type: Grant
    Filed: July 18, 2005
    Date of Patent: February 24, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yong-Jin Wu, Huan He
  • N-[4-Fluorophenyl)methyl]-4,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide as an HIV integrase inhibitor
    Patent number: 7491819
    Abstract: The invention encompasses a series of bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.
    Type: Grant
    Filed: September 22, 2006
    Date of Patent: February 17, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: B. Narasimhulu Naidu, Margaret E. Sorenson, Dawn DiGiugno
  • Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
    Patent number: 7485633
    Abstract: The invention encompasses compounds of Formula I, pharmaceutically acceptable salts thereof, compositions, and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.
    Type: Grant
    Filed: March 12, 2007
    Date of Patent: February 3, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: Nicholas A. Meanwell, Robert G. Gentles, Min Ding, John A. Bender, John F. Kadow, Piyasena Hewawasam, Thomas W. Hudyma, Xiaofan Zheng
  • Indolobenzazepine HCV NS5B inhibitors
    Patent number: 7473688
    Abstract: The invention encompasses compounds and salts of Formulas I, II, III, and IV as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.
    Type: Grant
    Filed: September 6, 2006
    Date of Patent: January 6, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: Carl P. Bergstrom, John A. Bender, Robert G. Gentles, Piyasena Hewawasam, Thomas W. Hudyma, John F. Kadow, Scott W. Martin, Alicia Regueiro-Ren, Kap-Sun Yeung, Yong Tu, Katharine A. Grant-Young, Xiaofan Zheng
  • Constrained compounds as CGRP-receptor antagonists
    Patent number: 7470680
    Abstract: The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.
    Type: Grant
    Filed: May 1, 2007
    Date of Patent: December 30, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Prasad V. Chaturvedula, Stephen E. Mercer, Haiquan Fang, Xiaojun Han, Guanglin Luo, Gene M. Dubowchik, Graham S. Poindexter
  • Constrained compounds as CGRP-receptor antagonists
    Patent number: 7470679
    Abstract: The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.
    Type: Grant
    Filed: May 1, 2007
    Date of Patent: December 30, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Stephen E. Mercer, Prasad V. Chaturvedula
  • Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
    Patent number: 7456167
    Abstract: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.
    Type: Grant
    Filed: May 24, 2007
    Date of Patent: November 25, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventor: Carl P. Bergstrom